Skip to Content Facebook Feature Image

5K Walk Event in Michigan to Raise Money for Hidradenitis Suppurativa

Business

5K Walk Event in Michigan to Raise Money for Hidradenitis Suppurativa
Business

Business

5K Walk Event in Michigan to Raise Money for Hidradenitis Suppurativa

2025-06-26 03:27 Last Updated At:03:45

NEW YORK, June 26, 2025 /PRNewswire/ -- On June 1, Dimora Medical, a continuous innovator in high-end medical care supplies, proudly participated as a sponsor in the HS Connect 5K Walk. This event served not only as a fundraising effort but also as an opportunity for education about Hidradenitis Suppurativa (HS).

Organized by HS Connect, a patient-centered nonprofit dedicated to supporting individuals impacted by Hidradenitis Suppurativa, the event aimed to shine a light on the reality of living with this chronic and often misunderstood condition. HS is a painful, inflammatory skin disorder characterized by recurring abscesses and lesions that frequently result in open wounds, scarring, and significant physical and emotional distress. While estimates vary, the HS Foundation suggests that approximately 1-2% of the U.S. population may be affected, though actual prevalence could range between 0.1% and 1%.

Despite its severity, treatment options for HS remain limited. Only three therapies have received FDA approval, and although off-label options are used to manage the disease, comprehensive care often depends on ongoing symptom management and wound care. For patients, maintaining quality of life requires not just medical intervention, but also access to appropriate wound treatment solutions that reduce discomfort and promote healing.

Dimora Medical's advanced silicone foam dressing solutions address this need of the HS community. The Dimora Silicone Foam Dressing with Border, for example, has been developed with both clinical performance and patient comfort in mind, particularly for individuals coping with the types of lesions and drainage associated with HS flare-ups.

This silicone foam dressing incorporates a five-layer material design capable of absorbing up to 15 times its weight in wound fluid. This feature ensures a consistently moist environment around the wound site, which is crucial for accelerating the healing process and reducing the frequency of dressing changes. At the same time, it creates a physical barrier that shields the wound from external contaminants.

Key to the dressing's effectiveness is the A+ medical-grade hypoallergenic silicone contact layer, which adheres securely to dry skin while avoiding adhesion to moist wounds. This balance minimizes pain and trauma during dressing changes, a frequent concern for HS patients. Additionally, the semi-permeable polyurethane film layer provides waterproof yet breathable protection, allowing oxygen and vapor transmission while preventing bacterial invasion.

Further enhancing its efficacy, the internal foam structure features a thick absorbent core, a SAF layer that locks in the fluid to prevent maceration, and a nonwoven layer that evenly disperses exudate. The result is a dressing that significantly outperforms traditional gauze bandages, reducing the burden of constant replacement and enabling patients to regain a sense of daily normalcy.

As part of its mission towards enhancing the quality of life through effective wound management solutions tailored specifically for those suffering from chronic conditions such as Hidradenitis Suppurativa, Dimora Medical remains dedicated not only through product innovation but also via active participation within communities advocating awareness around these often-misunderstood illnesses.

About Dimora Medical

Dimora, standing for Direct In-home Medical Options for Recovery and Aid, specializes in advanced wound care products tailored for middle-aged and elderly individuals. With a professional medical background, Dimora Medical is dedicated to enhancing quality of life by simplifying wound management and chronic disease care. The initial wound dressing concept aimed to help caregivers manage wounds efficiently, reducing the risk of secondary injuries. Evolving from wound care expertise to chronic disease management, Dimora Medical offers multi-scenario products to streamline home care, making life comfortable, easy, and convenient.

For more information, please visit: https://dimoramedical.com/ 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

5K Walk Event in Michigan to Raise Money for Hidradenitis Suppurativa

5K Walk Event in Michigan to Raise Money for Hidradenitis Suppurativa

T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors

Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer

Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.

"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."

Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.

 

 

To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.

Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.

"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."

About Alamar Biosciences, Inc. 
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Recommended Articles